EA200501018A1 - Офтальмологический препарат для профилактики и лечения болезненных состояний глаз - Google Patents
Офтальмологический препарат для профилактики и лечения болезненных состояний глазInfo
- Publication number
- EA200501018A1 EA200501018A1 EA200501018A EA200501018A EA200501018A1 EA 200501018 A1 EA200501018 A1 EA 200501018A1 EA 200501018 A EA200501018 A EA 200501018A EA 200501018 A EA200501018 A EA 200501018A EA 200501018 A1 EA200501018 A1 EA 200501018A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- eye
- conditions
- age
- drug
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Разработан офтальмологический препарат для профилактики и лечения неблагоприятных глазных состояний, включая пресбиопию (старческую дальнозоркость), помутнение роговицы (arcus senilis), возрастную дегенерацию желтого пятна и других состояний, связанных со старением. Препарат также можно использовать для профилактики и лечения других неблагоприятных глазных состояний, таких как связанные с окислительным и/или свободно радикальным повреждением глаза; данные состояния могут включать состояние, заболевание или нарушение роговицы, сетчатки, хрусталиков, склеры, переднего сегмента и заднего сегмента глаза. В одном варианте осуществления препарат содержит по крайней мере 0,6 мас.% биосовместимого хелатирующего агента, эффективное усиливающее проникновение количество усилителя проницаемости, такого как метилсульфонилметан (MSM), анти-AGE агент, т.е. соединение, которое служит для снижения присутствия конечных продуктов повышенного гликозилирования (AGE) в глазу, и фармацевтически приемлемый офтальмологический носитель, подходящий для конкретного типа препарата (например, глазные капли или мази). Предпочтительные компоненты препарата являются многофункциональными и имеют природное происхождение.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43584902P | 2002-12-20 | 2002-12-20 | |
US50647403P | 2003-09-26 | 2003-09-26 | |
PCT/US2003/041141 WO2004058289A1 (en) | 2002-12-20 | 2003-12-22 | Ophthalmic formulation for the prevention and treatment of ocular conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200501018A1 true EA200501018A1 (ru) | 2006-02-24 |
EA008496B1 EA008496B1 (ru) | 2007-06-29 |
Family
ID=32685411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200501018A EA008496B1 (ru) | 2002-12-20 | 2003-12-22 | Офтальмологический препарат для профилактики и лечения болезненных состояний глаз |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040137068A1 (ru) |
EP (2) | EP1972344A1 (ru) |
JP (1) | JP5583310B2 (ru) |
CN (1) | CN1753683B (ru) |
AU (1) | AU2003297511B2 (ru) |
CA (1) | CA2511217A1 (ru) |
EA (1) | EA008496B1 (ru) |
IL (1) | IL169287A (ru) |
NZ (1) | NZ540885A (ru) |
TW (1) | TWI361701B (ru) |
WO (1) | WO2004058289A1 (ru) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
EP3093040A1 (en) | 2004-07-02 | 2016-11-16 | Mati Therapeutics Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
NZ556456A (en) | 2005-01-20 | 2010-12-24 | Inst Molecular Medicine Inc | Methylphenidate derivatives and uses of them |
US20060172951A1 (en) * | 2005-01-28 | 2006-08-03 | Dantzig Paul I | Age related macular degeneration and cutaneous signs of mercury toxicity |
WO2006102212A2 (en) * | 2005-03-18 | 2006-09-28 | Deborah Zelinsky | Methods for diagnosis and treatment of processing difficulties, integration problems, imbalances and abnormal postures |
DK1919290T3 (da) | 2005-07-12 | 2014-04-22 | Ampio Pharmaceuticals Inc | Fremgangsmåder og produkter til behandling af sygdomme |
US20100069335A1 (en) * | 2005-07-15 | 2010-03-18 | Rajiv Bhushan | Prevention and Treatment of Ophthalmic Complications of Diabetes |
CA2615231A1 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Prevention and treatment of ophthalmic complications of diabetes |
CA2615360A1 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Formulation and method for administration of ophthalmologically active agents |
WO2007013591A1 (ja) * | 2005-07-29 | 2007-02-01 | Santen Pharmaceutical Co., Ltd. | ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム |
US8048896B2 (en) * | 2005-10-05 | 2011-11-01 | Cell Viable Corporation | Methods for inhibiting and breaking AGE complex formation |
US8053449B2 (en) * | 2005-10-05 | 2011-11-08 | Cell Viable Corporation | Method for inhibiting AGE complex formation |
US20070154523A1 (en) * | 2005-12-30 | 2007-07-05 | Rick Lewis | Controlled pupil dilation for diagnostic and treatment of visual anomalies |
CN101394844A (zh) * | 2006-02-14 | 2009-03-25 | 东弗吉尼亚医学院 | 甲氧基聚乙二醇硫酯螯合物及其用途 |
KR101454674B1 (ko) * | 2006-03-17 | 2014-10-27 | 존슨 앤드 존슨 비젼 케어, 인코포레이티드 | 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물 |
NZ571758A (en) | 2006-03-31 | 2012-06-29 | Quadra Logic Tech Inc | A drug insert surrounded by a sheath to expose a polymer containing a drug to surrounding tissues or an eye |
US20080138393A1 (en) * | 2006-12-11 | 2008-06-12 | Access To Business Group International Llc | Water soluble extract of spinach for prevention and repair of DNA damage |
BRPI0807943A2 (pt) * | 2007-02-15 | 2014-10-21 | Derma Young Ltd | Composição farmacêutica ou nutracêutica e métodos para melhorar a administração de um ingrediente farmacêutico pela mucosa oral e para supressão de apetite |
WO2009035562A2 (en) | 2007-09-07 | 2009-03-19 | Qlt Plug Delivery, Inc | Drug cores for sustained release of therapeutic agents |
CN101861135A (zh) | 2007-09-07 | 2010-10-13 | Qlt栓塞输送公司 | 泪道植入物检测 |
EP2254511A2 (en) * | 2008-03-27 | 2010-12-01 | Alcon, Inc. | Hydrogel intraocular lens and method of forming same |
WO2009134371A2 (en) | 2008-04-30 | 2009-11-05 | Qlt Plug Delivery, Inc. | Composite lacrimal insert and related methods |
CN102123713A (zh) * | 2008-05-09 | 2011-07-13 | Qlt栓塞输送公司 | 治疗青光眼和眼高血压的活性剂的持续释放递送 |
EP2300011A4 (en) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | METHODS AND THERAPEUTIC COMPOUNDS |
IT1393402B1 (it) * | 2008-08-28 | 2012-04-20 | Sooft Italia Spa | Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali |
CN102395401B (zh) * | 2009-02-12 | 2015-08-19 | 因赛普特有限责任公司 | 经由水凝胶塞的药物递送 |
US11464781B2 (en) * | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
IT1393712B1 (it) * | 2009-05-13 | 2012-05-08 | Bruschettini Srl | Composizioni oftalmiche per la riepitelizzazione, la cicatrizzazione, e la disinfezione dei tessuti oculari |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
SG177302A1 (en) * | 2009-06-22 | 2012-02-28 | Dmi Acquisition Corp | Methods and products for treatment of diseases |
SG2014008171A (en) | 2009-06-22 | 2014-04-28 | Ampio Pharmaceuticals Inc | Method for treatment of diseases |
WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
WO2012033792A2 (en) | 2010-09-07 | 2012-03-15 | Dmi Acquisition Corp. | Treatment of diseases |
US20120071502A1 (en) * | 2010-09-17 | 2012-03-22 | Cell Viable Corporation | Novel phenoxyisobutyric acid compounds and methods for synthesis |
US9622911B2 (en) | 2010-09-30 | 2017-04-18 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
EP2750660B1 (en) | 2011-08-29 | 2016-10-12 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US9566301B2 (en) | 2012-03-29 | 2017-02-14 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
EP2830627B1 (en) | 2012-03-29 | 2024-05-01 | Epion Therapeutics, Inc. | Ocular treatment solutions, delivery devices and delivery augmentation methods |
WO2013148895A1 (en) | 2012-03-29 | 2013-10-03 | Cxl Ophthalmics, Llc | Ocular cross-linking system and method for sealing corneal wounds |
IN2014DN10291A (ru) * | 2012-05-03 | 2015-08-07 | Rajiv Bhushan | |
CN102988331B (zh) * | 2012-05-31 | 2015-02-04 | 管孝君 | 2-巯基-3-丁醇用于制备抗晶状体混浊产品的用途 |
US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
EP2908853B1 (en) | 2012-10-21 | 2018-12-05 | University Of Rochester | Thy1 (cd90) as a therapy to control adipose tissue accumulation |
BR112015014261A8 (pt) | 2012-12-19 | 2019-10-08 | Ampio Pharmaceuticals Inc | composto de danazol, seu uso e formulação farmacêutica compreendendo este |
RU2694758C2 (ru) * | 2012-12-20 | 2019-07-16 | Раджив Бхушан | Антимикробные композиции |
CN103040823A (zh) * | 2013-01-22 | 2013-04-17 | 杭州雷索药业有限公司 | 长春西汀在制备抗血管生成类药物中的应用 |
US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
HUE040373T2 (hu) | 2015-04-29 | 2019-03-28 | Sooft Italia S P A | Kollagén-rostok javított térhálósító szerei cornealis ectasia kezelésében való alkalmazásra |
EP4385521A2 (en) * | 2015-06-18 | 2024-06-19 | Lenz Therapeutics, Inc. | Storage stable compositions and methods for the treatment of refractive errors of the eye |
PT3352766T (pt) * | 2015-09-24 | 2022-03-22 | Matrix Biology Inst | Composições de hialuronano de elevada elasticidade e processos para o seu uso |
US20190000754A1 (en) * | 2015-10-05 | 2019-01-03 | Seinda Biomedical Corporation | Therapeutic compositions for the treatment of dry eye and related ocular surface diseases |
CN108430496A (zh) * | 2015-11-13 | 2018-08-21 | 加州大学洛杉矶分校医疗中心洛杉矶生物医学研究所 | 用于治疗角膜病症的蛋白酶体调节 |
PT109154B (pt) | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
DE112017005954T8 (de) * | 2016-11-24 | 2019-10-24 | Groove X, Inc. | Autonom agierender Roboter, der die Pupille verändert |
WO2019136358A1 (en) * | 2018-01-05 | 2019-07-11 | Iveena Delivery Systems, Inc. | Treatment of myopic progression |
JP2021512847A (ja) * | 2018-02-05 | 2021-05-20 | リビオネックス・インコーポレイテッドLivionex, Inc. | キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤 |
CA3162141A1 (en) | 2018-04-24 | 2019-10-31 | Allergan, Inc. | Presbyopia treatments |
CA3145888A1 (en) * | 2018-07-31 | 2020-02-06 | Isilay KAVADARLI | Ophthalmic formulations and uses thereof |
EA202191683A1 (ru) * | 2018-12-18 | 2021-09-01 | Сантен Фармасьютикал Ко., Лтд. | Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
CN111632068A (zh) * | 2020-06-30 | 2020-09-08 | 云南农业大学 | 一种犬、猫干细胞眼用制剂及其应用 |
TW202337462A (zh) * | 2021-07-20 | 2023-10-01 | 海南先聲藥業有限公司 | 採用長春西汀治療近視的方法 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US659151A (en) * | 1900-02-19 | 1900-10-02 | Johann Muellfarth | Rotary engine. |
US4450150A (en) * | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4863748A (en) * | 1979-08-30 | 1989-09-05 | Herschler R J | Dietary products and uses comprising methylsulfonylmethane |
US4488148A (en) * | 1982-02-19 | 1984-12-11 | Becton, Dickinson And Company | Combination switching and display electronic modular control unit |
US4510778A (en) * | 1983-12-27 | 1985-04-16 | The Maytag Company | Control system for a combined appliance |
FR2588189B1 (fr) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US5989579A (en) * | 1986-10-02 | 1999-11-23 | Escalon Medical Corp. | Ocular insert with anchoring protrusions |
US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US4923693A (en) * | 1988-01-21 | 1990-05-08 | Sundrops Enterprises, Inc. | Ultraviolet radiation screening method for eyes |
US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5278142A (en) * | 1989-03-20 | 1994-01-11 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
AU5929190A (en) * | 1989-06-02 | 1991-01-07 | Aisi Research Corporation | Appliance interface for exchanging data |
US5005996A (en) * | 1989-09-15 | 1991-04-09 | International Business Machines Corporation | Ribbon cartridge with endless ribbon reinking mechanism |
IL95942A0 (en) * | 1989-10-13 | 1991-07-18 | Syntex Inc | Collagen-containing ophthalmic formulation |
US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
US5300295A (en) * | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
WO1993004690A1 (en) * | 1991-09-09 | 1993-03-18 | Peptide Technology Limited | Method for the treatment of the complications and pathology of diabetes |
ZA927277B (en) * | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
US5270051A (en) * | 1991-10-15 | 1993-12-14 | Harris Donald H | Enzyme-orthokeratology |
US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
US5982355A (en) * | 1993-11-05 | 1999-11-09 | Jaeger; Denny | Multiple purpose controls for electrical systems |
US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
ATE315939T1 (de) * | 1993-11-19 | 2006-02-15 | Univ Sydney | Verfahren zur prophylaxe oder kontrolle des katarakts |
FI119756B (fi) * | 1995-01-18 | 2009-03-13 | Alteon Inc | Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa |
MX9705449A (es) * | 1995-01-18 | 1998-02-28 | Alteon Inc | Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada. |
US5916288A (en) * | 1996-09-03 | 1999-06-29 | Ut Automotive Dearborn, Inc. | Multi-functional control switch arrangement |
CA2267320A1 (en) * | 1996-10-14 | 1998-04-23 | Hiroshi Miyata | Secondary cataract inhibitor |
DE19645678C2 (de) * | 1996-11-06 | 2000-05-25 | Preh Elektro Feinmechanik | Bedieneinheit zum Schalten und Steuern von Haushaltsgeräten |
CN1185953A (zh) * | 1996-12-27 | 1998-07-01 | 刘伟中 | 富氧舒眼液及其生产工艺 |
JP3638071B2 (ja) * | 1997-01-31 | 2005-04-13 | 矢崎総業株式会社 | システムスイッチ |
MX9701946A (es) * | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
US5817630A (en) | 1997-03-18 | 1998-10-06 | Austin Nutriceutical Corporation | Glutathione antioxidant eye drops |
DE69816980T2 (de) * | 1997-03-31 | 2004-07-22 | Alza Corp., Palo Alto | Implantierbares diffusionabgabesystem |
EP0872991B1 (en) * | 1997-04-15 | 2006-07-26 | Hewlett-Packard Company, A Delaware Corporation | Method and apparatus for device interaction by format |
US5811446A (en) * | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
RU2115412C1 (ru) * | 1997-04-22 | 1998-07-20 | Открытое акционерное общество "Нижегородский химико-фармацевтический завод" | Вагинальные суппозитории антибактериального действия |
US6265444B1 (en) | 1997-05-23 | 2001-07-24 | Insite Vision Incorporated | Ophthalmic composition |
US6159458A (en) * | 1997-11-04 | 2000-12-12 | Insite Vision | Sustained release ophthalmic compositions containing water soluble medicaments |
US6144888A (en) * | 1997-11-10 | 2000-11-07 | Maya Design Group | Modular system and architecture for device control |
US6555522B1 (en) * | 1998-02-05 | 2003-04-29 | Mount Sinai School Of Medicine Of The City Of New York | Peptides and other small molecules derived from regions of interacting proteins and uses thereof |
US6197934B1 (en) * | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
SE9802207D0 (sv) | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
WO2000024425A1 (en) * | 1998-10-27 | 2000-05-04 | Alcon Laboratories, Inc. | Preservative system for topically administrable pharmaceutical compositions |
US6171337B1 (en) * | 1999-03-31 | 2001-01-09 | Miles A. Galin | Positive power anterior chamber ocular implant |
CA2368688C (en) * | 1999-04-05 | 2009-08-11 | City Of Hope | Novel inhibitors of formation of advanced glycation endproducts (age's) |
US6548059B1 (en) * | 1999-07-22 | 2003-04-15 | The Schepens Eye Research Institute, Inc. | Promotion of proliferation of adult corneal endothelial cells |
US6463343B1 (en) * | 1999-08-10 | 2002-10-08 | International Business Machines Corporation | System and method for controlling remote devices from a client computer using digital images |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
CA2385703A1 (en) * | 1999-10-07 | 2001-04-12 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
EP1225879A2 (en) * | 1999-10-22 | 2002-07-31 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6348508B1 (en) | 2000-04-04 | 2002-02-19 | Bausch & Lomb Incorporated | Method for treating dry eye |
RU2165749C1 (ru) * | 2000-07-06 | 2001-04-27 | Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" | Способ восстановления эндотелия роговицы |
WO2002024116A1 (en) * | 2000-09-20 | 2002-03-28 | Shahinian, Lee, Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
US6587739B1 (en) * | 2000-09-29 | 2003-07-01 | Sunbeam Products, Inc. | Appliance communication and control system and appliances for use in same |
US7084130B2 (en) * | 2001-12-11 | 2006-08-01 | Alcon, Inc. | Intraocular irrigating solution having improved flow characteristics |
US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
US6533769B2 (en) * | 2001-05-03 | 2003-03-18 | Holmen Joergen | Method for use in cataract surgery |
AU2002310325A1 (en) * | 2001-06-08 | 2002-12-23 | Baylor College Of Medicine | Use of ozone for the prevention of infection caused by medical devices |
BR0206984A (pt) * | 2001-11-14 | 2004-02-03 | Alza Corp | Composições de depósito injetáveis e uso destas |
JP2003171276A (ja) * | 2001-11-30 | 2003-06-17 | Menicon Co Ltd | 眼精疲労改善眼科用組成物 |
US20030114460A1 (en) * | 2001-12-14 | 2003-06-19 | Allergan Sales, Inc. | Pharmaceutical conjugates with enhanced pharmacokinetic characteristics |
US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
JP2006504701A (ja) * | 2002-09-30 | 2006-02-09 | マーク・エー・バビザイェフ | 眼疾患の局所的治療方法、並びに、その治療用組成物及び治療用手段 |
WO2005041870A2 (en) * | 2003-10-24 | 2005-05-12 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
-
2003
- 2003-12-22 EA EA200501018A patent/EA008496B1/ru not_active IP Right Cessation
- 2003-12-22 EP EP08006597A patent/EP1972344A1/en not_active Withdrawn
- 2003-12-22 EP EP03814363A patent/EP1592435A4/en not_active Withdrawn
- 2003-12-22 NZ NZ540885A patent/NZ540885A/en not_active IP Right Cessation
- 2003-12-22 JP JP2005510058A patent/JP5583310B2/ja not_active Expired - Lifetime
- 2003-12-22 CN CN2003801099156A patent/CN1753683B/zh not_active Expired - Fee Related
- 2003-12-22 US US10/744,524 patent/US20040137068A1/en not_active Abandoned
- 2003-12-22 CA CA002511217A patent/CA2511217A1/en not_active Abandoned
- 2003-12-22 AU AU2003297511A patent/AU2003297511B2/en not_active Expired
- 2003-12-22 WO PCT/US2003/041141 patent/WO2004058289A1/en active Application Filing
- 2003-12-23 TW TW092136558A patent/TWI361701B/zh not_active IP Right Cessation
-
2005
- 2005-06-20 IL IL169287A patent/IL169287A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US20040137068A1 (en) | 2004-07-15 |
CN1753683A (zh) | 2006-03-29 |
EP1972344A1 (en) | 2008-09-24 |
TW200512014A (en) | 2005-04-01 |
EP1592435A1 (en) | 2005-11-09 |
EA008496B1 (ru) | 2007-06-29 |
NZ540885A (en) | 2009-02-28 |
TWI361701B (en) | 2012-04-11 |
JP2006514696A (ja) | 2006-05-11 |
CA2511217A1 (en) | 2004-07-15 |
WO2004058289A1 (en) | 2004-07-15 |
JP5583310B2 (ja) | 2014-09-03 |
AU2003297511B2 (en) | 2010-01-21 |
IL169287A (en) | 2010-12-30 |
EP1592435A4 (en) | 2008-01-23 |
AU2003297511A1 (en) | 2004-07-22 |
CN1753683B (zh) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200501018A1 (ru) | Офтальмологический препарат для профилактики и лечения болезненных состояний глаз | |
EP1904108B1 (en) | Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin | |
US6273092B1 (en) | Methods for treating various eye disorders | |
Alfonso et al. | Posterior chamber phakic intraocular lenses after penetrating keratoplasty | |
CN101304727A (zh) | 大分子聚集体存在相关病症,尤其是眼科疾病的治疗 | |
ZA200604403B (en) | Amelioration of macular degeneration and other ophthalmic diseases | |
EP1669075A1 (en) | Therapeutic agent for ageing macular degeneration | |
EP3980017A1 (en) | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality | |
AU2014382677A1 (en) | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration | |
KR20230042077A (ko) | 노안, 원시, 난시, 감소된 입체시, 및 감소된 대비 감도를 치료하기 위한 조성물 및 방법 | |
KR20170043655A (ko) | 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 | |
CN105188702A (zh) | 使用双嘧达莫的用于治疗眼睛疾病的组合物 | |
US20040106644A1 (en) | Composition for treatment of night sight problems(halos, comas and glare) after refractive surgery, intra ocular lens implant after lensectomy or intraocular implant in phakic patients comprising aceclidine employed at low concentrations | |
Cockburn et al. | Herpes zoster ophthalmicus | |
Rathi et al. | Surgically induced astigmatism in frown versus chevron incision in MSICS | |
MacGregor et al. | collagen cross-linking for Pellucid Marginal degeneration | |
Tidake et al. | Effect of UV Light on Diabetic Retinopathy in Pseudophakic Eye | |
US20230210821A1 (en) | Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality | |
Monden | Intraocular lenses in patients with uveitis | |
Bellamkonda et al. | Factors affecting post-operative astigmatism in superior and temporal approaches in Manual Small Incision Cataract Surgery | |
Nashi | To Study the Causes of Subnormal Vision After Manual Small Incision Cataract Surgery in Department of Ophthalmology, Kims Hubli | |
Curtis et al. | Complications of neodymium: yttrium-aluminum-garnet laser capsulotomy | |
SU1397037A1 (ru) | Способ хирургического лечени близорукости и астигматизма | |
Assouline | March consultation# 4 | |
Kahook | December consultation# 7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |